Andrea Scupola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Andrea Scupola has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Maria Antonietta Blasi
Ocular Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
3 shared publications Gabriela Grimaldi
Department of Ophthalmology, Vitreoretinal Service, Catholic University of Rome, 00168 Rome, Italy
2 shared publications- Angela Lanza
Department of Ophthalmology, Catholic University, 00168 Rome, Italy
1 shared publication - Antonio Villano
Department of Head and Neck Surgery, Ophthalmology Unit, Catholic University, Rome, Italy
1 shared publication - Carmela Grazia Caputo
Ocular Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy
1 shared publication - Clara Rizzo
Department of Neurosciences, Psychology, Drug Research, and Child Health, Eye Clinic, University of Florence, AOU Careggi, 50139 Florence, Italy
1 shared publication
Latest Publications
- Open Access
Central Serous Chorioretinopathy by Autofluorescence, Enface and SLO–Retromode Imaging
The aim of our study was to investigate the clinical features of central serous chorioretinopathy (CSC) with autofluorescence (AF), retromode (RM), and enface imaging. This retrospective study was conducted at Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome (Italy), between September and December 2022. Each patient underwent a complete ophthalmological examination, which included optical coherence tomography (OCT), enface image analysis, AF, and RM imaging. We further evaluated the presence and area of extension of serous retinal detachment and retinal pigment epithelium (RPE) atrophy through AF, RM, and enface imaging. We included 32 eyes from 27 patients (mean age: 52.7 ± 13.3 years). The median AF area was 19.5 mm2 (IQR 6.1–29.3), while the median RM area was 12.3 mm2 (IQR 8.1–30.8), and the median enface area was 9.3 mm2 (IQR 4.8–18.6). RPE atrophy was diagnosed in 26 cases (81.3%) with RM imaging and in 75% of cases with AF. No difference emerged between AF and RM analysis in the detection of central serous detachment in CSC. However, RM imaging showed a high specificity (91.7%) and negative predictive value (84.6%) to detect RPE changes when compared to the AF standard-of-care technique. Thus, RM imaging could be considered an adjunctive imaging method in CSC.
Open AccessCentral Serous Chorioretinopathy by Autofluorescence, Enface and SLO–Retromode Imaging
The aim of our study was to investigate the clinical features of central serous chorioretinopathy (CSC) with autofluorescence (AF), retromode (RM), and enface imaging. This retrospective study was conducted at Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome (Italy), between September and December 2022. Each patient underwent a complete ophthalmological examination, which included optical coherence tomography (OCT), enface image analysis, AF, and RM imaging. We further evaluated the presence and area of extension of serous retinal detachment and retinal pigment epithelium (RPE) atrophy through AF, RM, and enface imaging. We included 32 eyes from 27 patients (mean age: 52.7 ± 13.3 years). The median AF area was 19.5 mm2 (IQR 6.1–29.3), while the median RM area was 12.3 mm2 (IQR 8.1–30.8), and the median enface area was 9.3 mm2 (IQR 4.8–18.6). RPE atrophy was diagnosed in 26 cases (81.3%) with RM imaging and in 75% of cases with AF. No difference emerged between AF and RM analysis in the detection of central serous detachment in CSC. However, RM imaging showed a high specificity (91.7%) and negative predictive value (84.6%) to detect RPE changes when compared to the AF standard-of-care technique. Thus, RM imaging could be considered an adjunctive imaging method in CSC.
- Open Access
- 1 June 2018
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 10, 165-168
Morpho-functional evaluation of torpedo maculopathy with optical coherence tomography angiography and microperimetry
- 1 June 2018
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 10, 165-168
Open AccessMorpho-functional evaluation of torpedo maculopathy with optical coherence tomography angiography and microperimetry
- Open Access
- 7 February 2018
- Published by MDPI AG in Biomedicines
- Vol. 6 (1) , 17
Photodynamic Therapy in Ocular Oncology
Although introduced for the treatment of maculopathies, photodynamic therapy (PDT) is now largely used in some eye cancers treatment. The selective tissue damage with PDT is achieved by sequestration of the photosensitizer in the target tissue and focal activation of the photosensitizer by low energy directed light. In this way, it is possible to achieve the destruction of the tumor tissue by safeguarding the surrounding healthy structures. Our study describes the clinical uses and efficacy of photodynamic therapy in ocular oncology.
- 7 February 2018
- Published by MDPI AG in Biomedicines
- Vol. 6 (1) , 17
Open AccessPhotodynamic Therapy in Ocular Oncology
Although introduced for the treatment of maculopathies, photodynamic therapy (PDT) is now largely used in some eye cancers treatment. The selective tissue damage with PDT is achieved by sequestration of the photosensitizer in the target tissue and focal activation of the photosensitizer by low energy directed light. In this way, it is possible to achieve the destruction of the tumor tissue by safeguarding the surrounding healthy structures. Our study describes the clinical uses and efficacy of photodynamic therapy in ocular oncology.
- 5 January 2014
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 24 (5) , 803-807
Intravitreal Dexamethasone Implant for Acute Exudative Polymorphous Vitelliform Maculopathy
Purpose: Acute exudative polymorphous vitelliform maculopathy is a rare retinal disease characterized by bilateral serous macular detachment and subretinal accumulation of yellowish deposits resembling Best dystrophy lesions. Corticosteroid systemic therapy has been used empirically in the attempt to treat this retinal disorder with mixed results. Thus, the benefit of corticosteroid remains undetermined. To our knowledge, we report the first case of acute exudative polymorphous vitelliform maculopathy (AEPVM) treated in one eye with intravitreal dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, California, USA). Methods: A 28-year-old man with AEPVM underwent intravitreal dexamethasone implantation in the left eye. Results: Compared with the fellow eye, intravitreal dexamethasone implant did not significantly modify the clinical course of the disease. No implant-related complication was experienced during follow-up. Conclusions: The lack of response to intravitreal dexamethasone seems to suggest that corticosteroids may be ineffective for the treatment of AEPVM.
- 5 January 2014
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 24 (5) , 803-807
Intravitreal Dexamethasone Implant for Acute Exudative Polymorphous Vitelliform Maculopathy
Purpose: Acute exudative polymorphous vitelliform maculopathy is a rare retinal disease characterized by bilateral serous macular detachment and subretinal accumulation of yellowish deposits resembling Best dystrophy lesions. Corticosteroid systemic therapy has been used empirically in the attempt to treat this retinal disorder with mixed results. Thus, the benefit of corticosteroid remains undetermined. To our knowledge, we report the first case of acute exudative polymorphous vitelliform maculopathy (AEPVM) treated in one eye with intravitreal dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, California, USA). Methods: A 28-year-old man with AEPVM underwent intravitreal dexamethasone implantation in the left eye. Results: Compared with the fellow eye, intravitreal dexamethasone implant did not significantly modify the clinical course of the disease. No implant-related complication was experienced during follow-up. Conclusions: The lack of response to intravitreal dexamethasone seems to suggest that corticosteroids may be ineffective for the treatment of AEPVM.